**The development and validation of a prognostic model to PREDICT Relapse of depression in adult patients in primary care: protocol for the PREDICTR study**

Andrew S Moriarty\*1 2, Lewis W Paton1, Kym IE Snell3, Richard D Riley3, Joshua EJ Buckman4 5, Simon Gilbody1 2, Carolyn A Chew-Graham6, Shehzad Ali1 7, Stephen Pilling4 8, Nick Meader9, Bob Phillips9, Peter A Coventry1, Jaime Delgadillo10, David A Richards11 12, Chris Salisbury13, Dean McMillan1 2

1. Department of Health Sciences, University of York
2. Hull York Medical School, University of York
3. Centre for Prognosis Research, School of Medicine, Keele University
4. Centre for Outcomes and Research Effectiveness, Research Department of Clinical, Educational and Health Psychology, University College London
5. iCope – Camden and Islington Psychological Therapies Services, Camden & Islington NHS Foundation Trust
6. School of Medicine, Keele University
7. Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada
8. Camden & Islington NHS Foundation Trust, St Pancras Hospital
9. Centre for Reviews and Dissemination, University of York
10. Department of Psychology, University of Sheffield
11. Institute of Health Research, College of Medicine and Health, University of Exeter
12. Department of Health and Caring Sciences, Western Norway University of Applied Sciences, Inndalsveien 28, 5063 Bergen, Norway
13. Centre for Academic Primary Care, University of Bristol

\* Corresponding author: Dr Andrew S Moriarty; andrew.moriarty@york.ac.uk

**The development and validation of a prognostic model to PREDICT Relapse of depression in adult patients in primary care: protocol for the PREDICTR study**

**Abstract (350 words)**

**Background:** Most patients who present with depression are treated in primary care by general practitioners (GPs). Relapse of depression is common (at least 50% of patients treated for depression will relapse after a single episode) and leads to considerable morbidity and decreased quality of life for patients. The majority of patients will relapse within 6 months and those with a history of relapse are more likely to relapse in the future than those with no such history. GPs see a largely undifferentiated case-mix of patients and, once patients with depression reach remission, there is limited guidance to help GPs stratify patients according to risk of relapse. We aim to develop a prognostic model to predict an individual’s risk of relapse within 6-8 months of entering remission. The long-term objective is to inform the clinical management of depression after the acute phase.

**Methods:** We will develop a prognostic model using secondary analysis of individual participant data drawn from seven RCTs and one longitudinal cohort study in primary or community care settings. We will use logistic regression to predict the outcome of relapse of depression within 6-8 months. We plan to include the following established relapse predictors in the model: residual depressive symptoms; number of previous depressive episodes; co-morbid anxiety; and severity of index episode. We will use a “full model” development approach, including all available predictors. Performance statistics (optimism-adjusted C-statistic, calibration-in-the-large, calibration slope) and calibration plots (with smoothed calibration curves) will be calculated. Generalisability of predictive performance will be assessed through internal-external cross-validation. Clinical utility will be explored through net benefit analysis.

**Discussion:** We will derive a statistical model to predict relapse of depression in remitted depressed patients in primary care. Assuming the model has sufficient predictive performance, we outline the next steps including independent external validation, and further assessment of clinical utility and impact.

**Key words:** Relapse, recurrence, depression, prognosis, prognostic model, predictive model

**Study registration:** ClinicalTrials.gov ID: NCT04666662

**Introduction**

Depression is the leading cause of disability worldwide (1) and most people with depression are treated in primary care (2). Around half of patients will experience a re-emergence of depressive symptoms at some point after their initial symptoms have improved and, for the majority of these, this occurs within the first 6 months (3). Relapse and recurrence are both terms used to describe the re-emergence of depressive symptoms following some level of improvement. Generally relapse occurs after some improvement (remission) but before full recovery (4), whereas recurrence is the onset of a further, separate episode after full recovery. While there is no empirically derived temporal cut-off to distinguish relapse from recurrence, recovery is most commonly operationalized as following an extended period of remission; between 6-12 months (5). Relapse, then, occurs within 6-12 months, while recurrence occurs beyond 6-12 months (6,7).

The distinction between relapse and recurrence provides a useful theoretical framework and there may be some clinical relevance. The implication is that the re-emergence of symptoms in relapse is part of the unsuccessfully treated index episode of depression; while in recurrence it is attributable to a new and separate episode of depression. When the MacArthur Foundation Research Network defined these terms, or “change points”, in 1991 (4,7), their aim was to provide a framework that might be more consistently applied in the empirical literature, but also that the framework and definitions themselves be validated empirically by researchers. There have been limited attempts to do this, though where this has been attempted researchers have found some evidence to support their validity (8). Given the wide variability in the way in which the terms relapse and recurrence have been operationalized by researchers, however, Bockting et al. (2015) suggested using the terms interchangeably to describe the “re-emergence of symptoms following a period of relative wellness” (5). We will use the term *relapse* throughout this paper.

There is some evidence that the severity of depression (9) and risk of further relapse (10–12) increases with each subsequent depressive episode, highlighting the potential benefits of intervening early to prevent relapse and recurrence with a view to improving the overall trajectory of depression. Efforts to prevent relapse could be improved by an increased ability to predict prognosis and identify high-risk individuals. Prognosis can be shaped by multiple factors and, once it is established which factors are associated with an outcome, the information can be used to create a multivariable prognostic model. Prognostic models aim to provide individualised risk estimates for a specified outcome by a particular time conditional on the individual’s values for multiple prognostic factors (or predictors) (13). We currently lack evidence-based tools to assist clinicians with risk predictions of depressive relapse.

There have been some previous attempts to develop relapse prediction models for depression (14–18). These pre-existing prognostic models have some drawbacks with respect to successfully predicting relapse in a primary care context. Critical appraisal of these studies, using the Prediction model Risk Of Bias Assessment Tool (PROBAST), found that the majority of these studies were at high overall risk of bias. The most significant limitations were inadequate sample size, inappropriate handling of missing data, and presentation of inappropriate performance statistics (calibration and discrimination not assessed) (19). Furthermore, the developed models have either demonstrated insufficient predictive performance on external validation (14), or they could not be feasibly implemented in a primary care setting due to the large number and type of included predictors (17).

 This protocol outlines the methods for the development and validation of a novel prognostic model to predict an individual’s risk of relapse of depression in a primary care setting. The long-term aim, beyond this study, is to implement the prognostic model in clinical practice for use by primary care health professionals to enable optimal shared decision making with patients. The model must, therefore, be accurate, generalisable and effective (i.e. result in demonstrably improved outcomes for patients). In order to be implemented in practice, it must also be clinically credible and have face validity to healthcare professionals and patients.

**Objective**

To develop and validate a multivariable prognostic model to predict relapse within six to eight months in patients with remitted depression in primary care.

**Methods**

The methods have been developed in accordance with those recommended by the PROGnosis RESearch Strategy (PROGRESS) initiative (20,21) and the prognostic model will be published according to the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) Statement (22). This study will use individual participant data (IPD) from RCTs and a cohort study, therefore elements of the Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data (PRISMA-IPD) statement are also relevant (23). However, this study is not a systematic review and the aim is not to provide a summary of a complete body of research and so not all items are applicable.A Patient and Public Involvement (PPI) group of service users have informed several aspects of this study, including selecting predictors and their measurement (for example, commenting on the acceptability of validated diagnostic instruments for depression and anxiety symptoms), definition of outcome, target patient population and clinical application. The study has been registered prospectively on clinicaltrials.gov (available: ClinicalTrials.gov ID: NCT04666662).

***Source of data***

We have formed a cohort using IPD from UK primary care-based datasets. Along with cohort studies, RCTs are a recommended source of data for development of prognostic models (24). We had IPD readily available in a pragmatic sample of four RCTs (CASPER Plus (25), REEACT (26), REEACT 2 (27) and COINCIDE (28)), derived from RCTs carried out within our own research group. In order to increase the sample size available for model development, we identified further studies: first, by searching all National Institute for Health Research (NIHR)-funded RCTs of primary care-based interventions for depression and; second, by reference to the search results from a recent IPD meta-analysis of RCTs of depression interventions (this meta-analysis had searched for studies that had used the CIS-R as a measure of baseline severity and provided a recent search of relevant studies) (29).

To be included, we specified that RCTs must:

* Include adult patients (18 years and over) with depression and measure depressive symptoms at a minimum of three time-points (to enable diagnosis of depression, remission, relapse/no relapse). We excluded RCTs in patient groups with significant psychiatric or medical comorbidity. We also excluded feasibility studies (due to limited sample size and shorter follow-up time associated with those identified);
* Have sufficient follow-up to allow us to detect relapse within at least six months;
* Use only non-pharmacological interventions (e.g. psychological, social, behavioural). We excluded RCTs of pharmacological interventions, as these were felt likely not to be comparable to the pharmacological interventions that patients would be receiving from their primary care healthcare providers as usual treatment. Trials of pharmacological interventions often use medication combinations that would not be routinely prescribed in primary care and would therefore potentially reduce the generalisability of the model. Non-pharmacological interventions are more likely to affect outcomes in a comparable way;
* Use the Patient Health Questionnaire (PHQ-9) as a measure of depression.

This search added three further RCTs: COBRA (30), CADET (31) and Healthlines Depression RCT (32).

Finally, we contacted the authors of the West Yorkshire Low Intensity Outcome Watch (WYLOW) study, a longitudinal cohort study following up patients after low intensity cognitive behavioural therapy (LiCBT) through the Improving Access to Psychological Therapies (IAPT) service (3). See Table 1 for details of the final included studies.

All of the included studies had pragmatic and unrestrictive inclusion criteria, and so are expected to be representative of the target population. The final PREDICTR dataset is derived from all arms (control and intervention) of seven randomised controlled trials (RCTs) of low-intensity primary care-based interventions for depression (CASPER Plus, REEACT, REEACT 2, COINCIDE, CADET, COBRA, Healthlines) and one observational cohort study (WYLOW).

**Table 1:** Summary of primary sources of IPD

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **N** | **Study type** | **Inclusion criteria** | **Length of Follow-up** | **Follow up Points** | **Mean age (SD)** | **Gender (% Female)** | **RCT Intervention** | **Duration of RCT Intervention** |
| CASPER Plus | 485 (358 at 12 m) | RCT | 65 years or older with depression | 18 months | 0, 4, 12 and 18 months | Intervention group: 71.9 (6.03)Control: 71.6 (5.96) | Intervention group: 59.1Control: 63.1 | Collaborative care | 8-10 weeks |
| REEACT | 461 | RCT | Adults with depression | 24 months | 0, 4, 12 and 24 months | 39.86 (12.65) | 67 | cCBT | 6 weeks |
| REEACT 2 | 369 | RCT | Adults with depression | 12 months. | 0, 4 and 12 months | 40.6 (13.8) | 64.5 | cCBT | 4 months |
| COINCIDE | 387 | RCT | Adults with depression and multi-morbidity | 24 months | 0, 4, 12, 24 | 58.5 (11.7) | 38 | Collaborative care | 3 months |
| COBRA  | 440 | RCT | Adults with depression | 18 months | 0, 6, 12, 18 | 43.5 (14.1) | 66 | Behavioural Activation vs CBT | 16 weeks |
| CADET | 581 | RCT | Adults with depression | 12 months | 0, 4,12 | 44.4 (13.3) | 71.9 | Collaborative care | 14 weeks  |
| Healthlines Depression | 609 | RCT | Adults with depression | 12 months | 0, 4,8,12 | Intervention group: 49.1 (12.9)Control: 50 (12.8) | Intervention group: 69Control: 68 | Complex intervention (Integrated telehealth) | 12 months |
| WYLOW | 439 | Longitudinal observational cohort study | Adults with depression | 12 months (Start-point = Remission) | Monthly | 41.28 (14.59) | 59.7 | None (cohort are followed up after LiCBT) | NA |

***Participants***

Adult participants (aged 18 years and over) with depression. The included participants do not have significant psychiatric comorbidity (e.g. schizophrenia, bipolar affective disorder).

***Setting***

All data sources are primary care or community based.

***Start-point (remission)***

There are three important time-points: baseline for the RCT (i.e. the point at which patients were depressed); Follow-up 1 (FU1; to diagnose remission; t=0 for our prediction model study and corresponds with 4 month follow-up for RCTs) and Follow-up 2 (FU2; the intended prediction time and occurs at either 6 or 8 months after t=0; patient either relapses or does not relapse).

In all RCTs, the majority of participants are expected to meet criteria for a diagnosis of depression at baseline. Any participants identified to have a baseline PHQ-9 less than 10 will be excluded from the analysis. As described, FU1 is required to detect “remission” and FU2 to detect “relapse/no relapse”.

The start-point (or time of intended prediction) is FU1, the point at which a patient, who started treatment with case-level depression, has entered remission. The PHQ-9 is a screening tool for major depressive disorder and a cut-off of 10 or more is used to detect clinically significant depressive symptoms (33). Remission will be identified as a participant who had case-level depression at baseline (a PHQ-9 score of 10 or more) having i) a post-treatment PHQ-9 score below the established cut-off of 10 at 4 months after trial baseline (this is consistent with clinical recovery (31) as currently operationalized in the NHS Improving Access to Psychological Therapies (IAPT) service (3)) and ii) an improvement of ≥5 points on the PHQ-9 (which aligns with the established reliable change index used to identify those with “reliable improvement” (35)).

***End-point (relapse)***

Patients will be coded as relapsed if they fulfil the following criteria within six to eight months post-remission: i) PHQ-9 score above the diagnostic cut-off (10 or more) and ii) ≥5 points greater than their symptom score at the time of remission. As above, this is consistent with accepted criteria for reliable and clinically significant deterioration (35,36).

The main reason for specifying the prediction end-point at six to eight months rather than a single time point is pragmatic and based on the available data (the time between FU1 and FU2 is eight months for six of the seven RCTs and six months for COBRA). As discussed in the Introduction, relapse is most commonly operationalized as occurring between 6 and 12 months post-remission (37) and the majority of patients who do relapse do so within the first 6 months (3). Relapse by 6-8 months is felt to be an appropriate and sufficiently short-term timeframe for predictions to be meaningful and clinically useful for patients and primary care professionals.

***Predictors***

We identified predictors based on literature review and on clinical grounds through discussion of a multidisciplinary group including members of the research team and the PPI group supporting the project. Umbrella reviews (reviews of other systematic reviews and meta-analyses) are one of the highest levels of evidence for determining associations between predictors and outcomes when selecting predictors for inclusion in a prognostic model (38). A recently published umbrella review of prognostic factors associated with increased risk of relapse and recurrence guided the selection of candidate predictors for inclusion in the model (39). A further systematic review of prognostic factors, published after the umbrella review, supported those findings and was also used to guide our included predictors (40). In addition to this, we reviewed all existing prognostic models for predicting relapse or recurrence to explore other predictors used (final review not yet published) (19). All candidate predictors are based on self-report or clinical information and we have not included, for example, biomarkers and in-depth neuropsychological testing in an effort to ensure that the model is acceptable and usable in a primary care setting (41).

All included studies have information about key predictors, measured using reliable and validated tools. See the section on Missing Data for details of how missing predictor information will be handled. Categorisation of continuous predictors will be avoided in order to avoid loss of information and power to detect an association between predictors and outcomes (20).

The following variables have robust evidence for their role as relapse predictors and will be included in the model:

*PHQ-9 score at remission (residual depressive symptoms)*

Residual depressive symptoms is a strongly established predictor of relapse (39,40). and will be operationalized in this study using the Patient Health Questionnaire (PHQ-9) score. The PHQ-9 is a validated tool for screening and case-finding for depression (33), routinely used in primary care. Remission is defined as a PHQ-9 score below 10 (remission) and residual symptoms are defined as a PHQ-9 at remission of between 5-9 (35). Per the inclusion criteria for this study, all participants will meeting criteria for remission (i.e. PHQ-9 score of below 10); PHQ-9 score at remission (0-9) will be modelled as a continuous variable rather than binary (e.g. presence or absence of residual symptoms).

*Number of previous episodes of depression*

There is strong evidence that this is a significant predictor (39,40), albeit slightly less strong than for residual symptoms. We plan to model this as a dichotomous predictor. The coding of this variable in the original RCTs is variable (i.e. a combination of continuous and dichotomous), and so it would not be possible to model as a continuous variable in this study. While there is some weak evidence that the relapse risk increases with each successive depressive episode, the prognostic effect of previous episodes on recurrence is strongest when comparing any number of previous episodes to no previous episodes (39). This finding from the pre-existing literature is likely to be helpful for a primary care based prognostic model, as there is potential difficulty in achieving a precise number of previous episodes in clinical practice. In this study, we will model this predictor as a dichotomous variable (0=no previous episodes, 1=one or more previous episodes) and will accept patient report, GP report or documentation in GP records.

*Comorbid anxiety*

There is good evidence that comorbid anxiety predicts relapse or recurrence of depression and will be included as a predictor in the model (39,40). The GAD-7 is a valid tool for screening and assessing severity of Generalised Anxiety Disorder score in clinical practice (42). Pre-treatment symptoms (i.e. those at baseline) seem to be more predictive of relapse than those at depressive remission (40). The pre-treatment GAD-7 score will be used provided it is available for all datasets; otherwise we will use the GAD-7 at remission (t=0). GAD-7 score will be modelled as a continuous predictor.

*Severity of episode*

There is reasonable evidence that the baseline severity of the *index* episode is a prognostic indicator of greater odds of relapse (39). This will be measured using the PHQ-9 score at baseline (pre-treatment) rather than that at the point of prognostication (remission). The PHQ-9 score at the point of depression diagnosis will be modelled as a continuous predictor.

*RCT Intervention*

Because the data are drawn from RCTs, we must be mindful of the fact that approximately half of the participants have received a treatment (above usual care) and the other half have not. Where the treatments were found to be effective, not modelling the effect of different treatments can lead to unreliable risk predictions when the model is validated in a different population. Excluding the treated individuals would mean losing half of the available data, and so a preferable option is to explicitly model for treatment effect when developing a prognostic model (43,44). The treatments in all RCTs were acute-phase psychological treatments rather than relapse prevention interventions, and therefore we do not know what their effect on relapse outcomes were. One of the studies (32) did include an element of relapse prevention beyond the acute phase treatment (advisors phoned the patients every 2 months to check how they were getting on and encourage them to keep following the intervention advice). The interventions are also heterogeneous and so it is possible that they affected relapse outcomes in different ways. To avoid overcomplicating the model, we will code presence or absence of an effective intervention as a dichotomous variable. We will define an effective intervention by whether individual participants entered remission after receiving an RCT intervention (code=1) or whether they entered remission after receiving a control (code=0).

**Table 2:** Summary of selected predictors

|  |  |  |  |
| --- | --- | --- | --- |
| **Predictor**  | **Type of data** | **Method of measurement** | **Range of values and coding of predictors** |
| PHQ-9 score at point of remission (residual depressive symptoms) | Continuous | PHQ-9 score at remission (t=0) | Range from 0-9 |
| Number of previous episodes of depression | Categorical | Patient or GP report (No previous episodes vs any previous episodes) | No previous episodes=0; 1 or more previous episodes=1 |
| Comorbid anxiety | Continuous  | GAD-7 Score | 0-21 |
| Severity of episode | Continuous | PHQ-9 score at baseline  | 10-27 |
| RCT Intervention | Categorical | Presence or absence of effective treatment | Remission after receiving control=0; Remission after receiving intervention=1 |

***Sample size***

Ensuring an adequate sample size will allow for more accurate estimation of regression coefficients and reduce the potential for overfitting. Rules of thumb for calculating required sample size for prediction models with binary outcomes (such as ten Events Per candidate predictor Parameter (EPP)) are now considered too simplistic to provide robust estimates of minimum required sample size (45). The actual required sample size is context-dependent and is informed by several factors. We used the *pmsampsize* package in Stata (available online: <https://riskcalc.org/pmsamplesize/>) to calculate our required minimum sample size (46).

The Cox-Snell R2 is a measure of overall model fit and based on the method of Riley et al. (46) an anticipated Cox-Snell R2 must be specified when calculating sample size, usually based on previous studies of similar patient groups/outcomes. No previous prognostic model study predicting relapse of depression identified so far has reported a Cox-Snell R2 and so, to ensure an adequate minimum sample size, we used the recommended conservative estimated Nagelkerke R2 of 15% (47). This corresponds to a Cox-Snell R2 of 0.0945, assuming an overall outcome proportion of 0.2, which again is a conservative estimate based on the literature (3). We targeted an expected shrinkage factor (*S*) of 0.9 (to reflect small optimism in predictor effect estimates), as recommended (47).

To include all predictors, we require 8 predictor parameters (*P*), which corresponds to PHQ-9 score at remission; Previous depressive episodes; Co-morbid anxiety; Severity of index episode; and RCT Intervention (including 2 parameters for each continuous predictor to account for potential non-linear trends). Therefore, our minimum required sample size (*n*) is 722 (with 145 events) for these predictors. Our actual sample size exceeds this and therefore we anticipate that the study will be of a sufficient size to require minimal shrinkage and provide meaningful estimates of predictive performance.

***Missing data***

To avoid loss of power and precision, missing data will be handled using multiple imputation with chained equations (MICE) (48). Missing values will be imputed based on other predictor and outcome values, under a missing at random assumption, and multiple copies of the dataset will be created with identical known information and different imputed values, reflecting the uncertainty associated with imputation. Imputation will be undertaken for each RCT separately, to preserve the clustering of participants within trials and any between-trial heterogeneity in predictor effects and outcome prevalence. We will assume that data are missing at random, unless this appears inappropriate upon inspection and discussion with original trialists. We will use the percentage of participants with one or more missing values to determine the number of imputations needed, in line with current guidance; at least 20, as long as this is greater than or equal to the percentage of participants with one or more missing values (20,49). Results from non-imputed and imputed data will be compared as a form of sensitivity analysis. Given the selection criteria, we do not anticipate any systematically missing predictors across datasets.

***Statistical analysis methods***

*Data pre-processing*

The datasets will be combined and harmonised to ensure consistency across trials. To assess IPD integrity, we will compare numbers of participants in each treatment arm with those reported in the primary references. We will check the relapse rate within each arm and compare these across datasets. To define the quality of the IPD for prognostic modelling, we will perform risk of bias assessment on the included datasets using the PROBAST (50). Only the participants, predictors and outcome domains are pertinent; the analysis domain is used for assessment of prognostic model development and validation studies which does not apply to the RCTs included in this study.

Once remission has been identified this will represent time t=0. Relapse will then be coded as 0=no relapse, 1=relapse as described in “End-point” section. Descriptive statistics will be produced for all predictors and outcome data. Exploratory univariable analysis will be performed to evaluate the unadjusted relationship between each predictor variable and the outcome variable, but not for the purpose of informing predictor selection. We will explore percentage of cases that relapse over the different studies to assess comparability of data sources.

*Model development*

The model will be developed using a multilevel multivariable logistic regression, with a binary (relapse/no relapse) outcome. Model parameters will be estimated via unpenalised maximum likelihood estimation, and then penalised post-estimation using a uniform shrinkage factor (see later). The modelling will preserve the clustering of patients within trials, by having a random effect on the intercept, a random intervention effect and a random control effect, also allowing for between-study correlation in these pair of effects. If it is not possible to fit random effects in the multilevel logistic regression model, as originally planned, we will explore alternative modelling approaches. This would initially consist of a Generalised Estimating Equation model to control for the clustering without a random intercept. If this is also not possible, we will perform single level analysis with robust standard errors, and accept that the limitation is that there may be a clustering effect that we are unable to properly control for.

Stepwise methods for predictor selection are not generally recommended for prediction models as this has been reported to remove judgment of the analyst from the process of model development as well as leading to *estimation bias* (estimating the performance of a prediction model after testing for statistical significance of predictors in the same data) (38). We have selected our key predictors on the grounds of best available evidence and clinical acceptability, as well as practical reasons related to data availability. The list of predictors is felt to be of appropriate length so we will avoid predictor selection techniques during model development and include all predictors regardless of their statistical significance (“full model” approach) (51). This will also apply in the presence of multi-collinearity, which is not an issue for prediction purposes. We will only consider the need to exclude predictors due to collinearity if this is preventing convergence of the estimated model.

The full model approach described has the advantage of not being overly data-dependent and avoids the risk of removing clinically important predictors from the final model (51). Calibration plots with loess smoothed calibration curves will be provided. Optimism will be measured and adjusted for using bootstrapping.

We will explore non-linear relationships in the modelling process using multivariable fractional polynomials (MFPs), a flexible and recommended approach for modelling continuous predictors in medical datasets. The other recommended method for modelling continuous predictors is the use of restricted cubic splines, and while these two methods often result in similar models, there is some evidence that MFPs perform better than restricted cubic splines in the presence of simpler relationships and medium amounts of information, as is the case here (21,52). We have factored in two predictor parameters (beta coefficients) per continuous variable to account for this approach, as described in the “Sample size” section.

*Internal validation*

The predictive performance and optimism of the developed model will then be assessed. Calibration (a measure of the agreement between predictions from the model and observed outcomes) will be assessed by plotting observed vs predicted risks for groups defined by tenths of individual predicted risk (calibration plot), and by including a loess smoothed calibration curve across individuals (avoiding grouping). Apparent and optimism-adjusted calibration-in-the-large and calibration slope will be estimated. Discrimination (the ability of the model to differentiate between those who do or do not relapse) will be assessed using the C (concordance) index. The C-index assesses the extent to which the model assigns a higher probability of relapse to a patient who did eventually relapse in contrast to a patient who did not. The optimism-adjusted C-index will be derived using bootstrapping.

Optimism describes the risk of obtaining misleading measures of predictive accuracy when this is assessed in the same dataset used for model development, mainly due to overfitting. Internal validation can be used to provide optimism-corrected performance statistics can mitigate for this effect. Non-parametric bootstrapping will be used as a means of resampling the original dataset. This has the advantage, for example over a single split-sample approach, of allowing all of the data to be used in model development. Bootstrapping will be performed within each individual study and then these will be combined to create a new bootstrap sample to ensure studies are represented evenly for the final analysis. Multiple imputation for missing data will be performed within each bootstrap sample.

A bootstrap sample will be created in which the model development process will be repeated. The performance of this model will be evaluated in the bootstrap sample (bootstrap, or apparent, performance) and in the original sample (test performance). This process will be repeated hundreds of times and the average difference between the bootstrap and test performance for each performance statistic provides the estimate of optimism for that statistic. Optimism-adjusted performance statistics will be derived by subtracting the average optimism estimate (from bootstrapping) from the apparent performance *of the original model*. The uniform shrinkage factor (calculated as the optimism-adjusted calibration slope) will then be applied to all estimated predictor effects to produce a penalised logistic regression model, and the intercept updated to ensure calibration-in-the-large.

Sensitivity, specificity and positive and negative predictive values for the model will be calculated at risk thresholds considered potentially clinically relevant. It is unclear whether the creation of risk groups is in the best interests of patients but they are often used to guide clinical decision making (22). In the absence of a gold standard test (as is the case here), the need for and definition of risk groups will be determined based on discussion within the research team and through consultation with our PPI group during model development. We will avoid basing risk thresholds on the data used to develop the model. The net benefit of the model at particular thresholds will also be examined using decision curve analysis, and compared to treat all and treat none decisions (53).

*External validation*

External validation is the assessment of a model’s predictive performance in data not used in the development process and is a measure of a model’s generalisability and performance in a range of populations and settings. To conserve information and to allow for all data to be used for model development, we do not plan to perform a conventional external validation as part of this study. We do, however, have IPD from multiple studies and, therefore, generalisability and heterogeneity of the model performance will be examined using internal-external cross-validation (IECV) (54), as follows. We will exclude data from each primary study in turn and develop the risk prediction model using the remaining data. We will then externally validate the developed model using the data from the excluded study. This process will be repeated, each time omitting a different study, until the model has been fitted excluding each study once. Random effects meta-analysis will then be used to summarise the performance across studies, to obtain summary measures of the model performance and estimates of heterogeneity in performance across studies. We will ensure that each cycle of the IECV approach retains sufficient sample size for model development; in this manner, each cycle will retain the majority of the available IPD for model development, and so the final models produced in each cycle are likely to be similar to each other. A consistent model development strategy will be used in each cycle of the IECV approach (55).

A sensitivity analysis will be performed measuring predictive performance statistics omitting, first, the observational cohort data (WYLOW) and secondly, the RCT (COBRA) with relapse at six, rather than eight, months. If our risk of bias (PROBAST) assessment identifies any studies that are not at overall low risk of bias, we will also perform a sensitivity analysis omitting these studies.

**Discussion**

We have reported a protocol for the development and validation of a novel prognostic model to predict depressive relapse in a primary care setting. As discussed, we have used an up-to-date review of the extant literature to guide predictor selection and our sample size is in excess, relative to the number of predictor parameters, of those used in previous prognostic model studies. We now briefly discuss our anticipated next steps, beyond this prognostic model study.

It is envisaged that this statistical model could form the basis for a clinical tool, to be embedded in GP IT systems, to help identify patients who are at higher risk of relapse. Longer term, and with further research, a decision tool could be developed to help inform decisions as to which patients with remitted depression should receive relapse prevention interventions. Provided we are able to demonstrate sufficient predictive accuracy during the validation stages, the model should undergo external validation (in a different dataset, to assess generalizability) and, ideally, independent validation (by a different research team, to reduce risk of bias). External validation could be done on either an unrelated retrospective dataset or, preferably, a prospective dataset collected specifically for this purpose. Finally, the impact of the model should be evaluated, and the gold standard way of doing this is through a randomised controlled trial with clinically meaningful outcome measures (56).

Qualitative work with stakeholders will be used to decide the extent to which the model can be implemented and will guide the evaluation of the model in practice, including plans for impact assessment. In particular, Cuijpers recently highlighted the importance of assessing the effect of mental health treatments on patient-defined outcomes (e.g. quality of life and functional outcomes) as well as those determined to be important by researchers or clinicians (57). This is applicable to health technologies, like prognostic models, and exploring patient-defined outcomes will form a part of our evaluation process beyond this study.

***Limitations***

The ideal dataset for developing a prognostic model is a prospective, pre-designed cohort study. The advantage of such an approach is that investigators retain control over inclusion and exclusion criteria, definition and measurement of predictors and outcomes, ensure appropriate timings, reduce missing data and minimize other potential biases (for example. selecting bias and blinding). However, the costs (financial and time) of carrying out a prospective study would be substantial and secondary analysis of good quality data from RCT and other cohorts is an accepted alternative (24). We are mindful of the potential problems with this approach, particularly the risk of missing data (that we have planned for) and the chance that predictors and outcomes may not be recorded optimally. We are reliant on the quality of the initial data collection with respect to this latter point and we are confident that the studies included are of a high standard.

A further common pitfall of RCTs is the narrow eligibility criteria often stipulated which can impact on the generalizability of any findings to the target population of interest (in our case, a primary care patient population). We are reassured that the eligibility criteria for included studies were inclusive and pragmatic with relatively small numbers of participants with missing data. We do however recognise that RCT participants may differ from the general population in important ways and results should be interpreted with this in mind.

In the planning stage of this project, we considered other data sources, in particular the Clinical Practice Research Datalink (CPRD), a large electronic database of routinely collected follow-up data from primary care. Following discussions with CPRD experts at the University of York, it was evident that the coding of measures of relapse and recurrence were not optimal for identifying patients who relapsed and that this would have limited our ability to develop a reliable and generalisable model.

Further limitations relate to measurement of start-point (remission) and end-point (relapse or not), which will be measured using PHQ-9 score. The gold standard would have been to use diagnostic interviews, which may have been possible with a prospective cohort study. The PHQ-9 is a validated and widely-used tool with good sensitivity and specificity (58) and the large sample size (possible because of the use of secondary data analysis) should compensate for this. A further point to consider is that the start- and end-points are defined at the next time-point they were actually measured rather than necessarily capturing the precise “real-world” moment of remission. However, this reflects the situation in general practice, where diagnostic tools will be applied at patient consultation rather than in real time. Therefore, we feel this is justifiable and actually mirrors the clinical picture accurately. We will use the reliable clinical recovery and deterioration definitions (sample size allowing) to ensure robust coding of start- and end-points.

In the event that multilevel modelling with a random intercept and random effects on the Intervention/control variable is not possible, we will be required to make an assumption that the effects of the different interventions and controls in the RCTs were homogenous. It is not likely that the interventions had a significant effect on relapse rates, even where they did improve acute depression symptoms. However, it is possible that one or more of the interventions (or controls) did exert an effect on relapse of which we are not aware. We will take a pragmatic approach to modelling this, following the steps that we have outlined in the Methods. A further limitation is that the data we plan to analyse do not allow for survival analysis, as the follow-up time-points were insufficiently similar and infrequent. However, time to relapse is important and would increase our understanding; future prospective work should consider this when designing strategies for data collection.

There are some predictors not included due to lack of relevance and usefulness to GPs. For example, neuroticism (the personality trait), childhood maltreatment and rumination have been found to be associated with increased risk of relapse and recurrence (39), as has duration of index episode of depression and age at onset of first episode of depression (59). These are not routinely measured in practice and have not been coded for in our cohorts; they will therefore not be included as predictors. The cohort has been designed to be as undifferentiated as possible to represent a GP case-mix. Increased predictive performance would be more likely if we were to be very specific in defining this cohort, but this would have implications for its utility in the real-world primary care setting.

This study will derive a statistical model aiming to predict relapse. If it demonstrates sufficient predictive performance, it could be used to guide the allocation of interventions to prevent relapse in a primary care setting, improving outcomes for patients and ensuring efficient use of healthcare resources.

**List of abbreviations**

CADET: The Clinical and Cost Effectiveness of Collaborative Care for Depression in UK Primary Care Trial

CASPER: CollAborative care for Screen-Positive EldeRs

CBT: Cognitive Behavioural Therapy

cCBT: Computerised Cognitive Behavioural Therapy

COBRA: Cost and Outcome of Behavioural Activation versus Cognitive Behaviour Therapy for Depression

COINCIDE: Collaborative Interventions for Circulation and Depression

GAD: Generalised anxiety disorder

GP: General practitioner

IPD: Individual participant data

LiCBT: Low-intensity Cognitive Behavioural Therapy

MFP: Multivariable fractional polynomials

PHQ-9: Patient Health Questionnaire

PROBAST: Prediction model Risk Of Bias Assessment Tool

RCT: Randomised controlled trial

REEACT: Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy

WYLOW: West Yorkshire Low-intensity Outcomes Watch

**Declarations**

***Ethics approval and consent to participate***

The University of York’s Health Sciences Research Governance Committee confirmed that this study is exempt from full ethical approval as it entails the secondary analysis of anonymised data from studies that had already received ethical approval.

***Consent for publication***

Not applicable.

***Availability of data and materials***

Not applicable.

***Competing interests***

The authors declare that they have no competing interests.

***Funding***

This report is independent research supported by the National Institute for Health Research (NIHR Doctoral Research Fellowship, Dr Andrew Moriarty, DRF-2018-11-ST2-044). Dr Kym Snell is funded by the NIHR School for Primary Care Research (SPCR Launching Fellowship). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. Dr Joshua Buckman was supported by the Wellcome Trust through a Clinical Research Fellowship (201292/Z/16/Z), Professor Stephen Pilling was supported by the Higher Education Funding Council for England, and the National Institute of Health Research (NIHR), NIHR University College London Hospitals Biomedical Research Centre.

***Authors' contributions***

ASM is the lead author, conceived the study and was responsible for writing the first draft of the manuscript.

LWP, KIES and RDR have provided methodological expertise and contributed to the statistical analysis plan.

NM and RPS provided specific methodological expertise.

JEJB and SP provided content and methodological expertise and commented on the final manuscript.

SG, DM, CCG and SA were all involved in the conception of the study.

PAC, DAR, CS, JD provided data for inclusion in the PREDICTR dataset and have commented on the final manuscript.

All authors read and approved the final manuscript.

***Acknowledgements***

The authors thank Professor Trevor Sheldon and Dr Paul Tiffin, who provided advice and comments at various stages of developing this Protocol through their Thesis Advisory Panel roles. Thanks also to the Public and Patient Involvement (PPI) group who have helped to shape this project and continue to provide valuable input.

***Authors' information (optional)***

***References***

1. Geneva: World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization. 2017.

2. Rait G, Walters K, Griffin M, Buszewicz M, Petersen I, Nazareth I. Recent trends in the incidence of recorded depression in primary care. Br J Psychiatry. 2009;195(6):520–4.

3. Ali S, Rhodes L, Moreea O, McMillan D, Gilbody S, Leach C, et al. How durable is the effect of low intensity CBT for depression and anxiety? Remission and relapse in a longitudinal cohort study. Behav Res Ther. 2017;94:1–8.

4. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and Rationale for Consensus Definitions of Terms in Major Depressive Disorder: Remission, Recovery, Relapse, and Recurrence. JAMA Psychiatry. 1991 Sep;48(9):851–5.

5. Bockting CL, Hollon SD, Jarrett RB, Kuyken W, Dobson K. A lifetime approach to major depressive disorder: The contributions of psychological interventions in preventing relapse and recurrence. Clin Psychol Rev. 2015;41:16–26.

6. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and Rationale for Consensus Definitions of Terms in Major Depressive Disorder: Remission, Recovery, Relapse, and Recurrence. JAMA Psychiatry. 1991;48(9):851–5.

7. Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31(9):1841–53.

8. Riso LP, Thase ME, Howland RH, Friedman ES, Simons AD, Tu XM. A prospective test of criteria for response, remission, relapse, recovery, and recurrence in depressed patients treated with cognitive behavior therapy. J Affect Disord. 1997;43(2):131–42.

9. Kendler KS, Thornton LM, Gardner CO. Stressful Life Events and Previous Episodes in the Etiology of Major Depression in Women: An Evaluation of the “Kindling” Hypothesis. Am J Psychiatry. 2000;157(8):1243–51.

10. Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. Comorbidity of DSM–III–R Major Depressive Disorder in the General Population: Results from the US National Comorbidity Survey. Br J Psychiatry. 1996;168(S30):17–30.

11. Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007;27(8):959–85.

12. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry. 2000;157(2):229–33.

13. Royston P, Moons KGM, Altman DG, Vergouwe Y. Prognosis and prognostic research: Developing a prognostic model. BMJ. 2009;338:b604.

14. Klein NS, Holtman GA, Bockting CLH, Heymans MW, Burger H. Development and validation of a clinical prediction tool to estimate the individual risk of depressive relapse or recurrence in individuals with recurrent depression. J Psychiatr Res. 2018;104:1–7.

15. van Loo HM, Aggen SH, Gardner CO, Kendler KS. Multiple risk factors predict recurrence of major depressive disorder in women. J Affect Disord. 2015;180:52–61.

16. Van Loo HM, Aggen SH, Gardner CO, Kendler KS. Sex similarities and differences in risk factors for recurrence of major depression. Psychol Med. 2018;48(10):1685–93.

17. van Loo HM, Bigdeli TB, Milaneschi Y, Aggen SH, Kendler KS. Data mining algorithm predicts a range of adverse outcomes in major depression. J Affect Disord. 2020;276:945–53.

18. Wang JL, Patten S, Sareen J, Bolton J, Schmitz N, MacQueen G. Development and validation of a prediction algorithm for use by health professionals in prediction of recurrence of major depression. Depress Anxiety. 2014;31(5):451–7.

19. Moriarty AS, Meader N, Gilbody S, Chew-Graham CA, Churchill R, Ali S, et al. Prognostic models for predicting relapse or recurrence of depression. Cochrane Database Syst Rev. 2019;2019(12).

20. Riley RD, van der Windt D, P C, Moons K. Prognosis Research in Healthcare: Concepts, Methods, and Impact. First edit. Oxford University Press.; 2019.

21. Steyerberg EW. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. Second Edi. Springer Nature Switzerland AG; 2019.

22. Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): Explanation and elaboration. Ann Intern Med. 2015;162(1):W1–73.

23. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data: The PRISMA-IPD statement. JAMA - J Am Med Assoc. 2015;313(16):1657–65.

24. Pajouheshnia R, Groenwold RHH, Peelen LM, Reitsma JB, Moons KGM. When and how to use data from randomised trials to develop or validate prognostic models. Bmj. 2019;2154

25. Bosanquet K, Adamson J, Atherton K, Bailey D, Baxter C, Beresford-Dent J, et al. Collaborative care for screen-positive elders with major depression (CASPER plus): A multicentred randomized controlled trial of clinical effectiveness and cost-effectiveness. Health Technol Assess (Rockv). 2017;21(67):1–251.

26. Gilbody S, Littlewood E, Hewitt C, Brierley G, Tharmanathan P, Araya R, et al. Computerised cognitive behaviour therapy (cCBT) as treatment for depression in primary care (REEACT trial): Large scale pragmatic randomised controlled trial. BMJ. 2015;351:1–13.

27. Gilbody S, Brabyn S, Lovell K, Kessler D, Devlin T, Smith L, et al. Telephone-supported computerised cognitive-behavioural therapy: REEACT-2 large-scale pragmatic randomised controlled trial. Br J Psychiatry. 2017;210(5):362–7.

28. Coventry P, Lovell K, Dickens C, Bower P, Chew-Graham C, McElvenny D, et al. Integrated primary care for patients with mental and physical multimorbidity: Cluster randomised controlled trial of collaborative care for patients with depression comorbid with diabetes or cardiovascular disease. BMJ. 2015;350:1–11.

29. Buckman JEJ, Saunders R, Cohen ZD, Clarke K, Ambler G, Derubeis RJ, et al. What factors indicate prognosis for adults with depression in primary care? A protocol for meta-analyses of individual patient data using the dep-gp database. Wellcome Open Res. 2020;4:1–20.

30. Richards DA, Ekers D, McMillan D, Taylor RS, Byford S, Warren FC, et al. Cost and Outcome of Behavioural Activation versus Cognitive Behavioural Therapy for Depression (COBRA): a randomised, controlled, non-inferiority trial. Lancet. 2016;388(10047):871–80.

31. Richards DA, Hill JJ, Gask L, Lovell K, Chew-Graham C, Bower P et al. Clinical effectiveness of collaborative care for depression in UK primary care (CADET): Cluster randomised controlled trial. BMJ. 2013;347(f4913).

32. Salisbury C, O’Cathain A, Edwards L, Thomas C, Gaunt D, Hollinghurst S, et al. Effectiveness of an integrated telehealth service for patients with depression: A pragmatic randomised controlled trial of a complex intervention. The Lancet Psychiatry. 2016;3(6):515–25.

33. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.

34. Clark DM. Realising the Mass Public Benefit ofClark, D. M. (2018). Realising the Mass Public Benefit of Evidence-Based Psychological Therapies : The IAPT Program. Annual Review of Clinical Psychology, 7(14), 159–183.

35. McMillan D, Gilbody S, Richards D. Defining successful treatment outcome in depression using the PHQ-9: A comparison of methods. J Affect Disord. 2010;127(1–3):122–9.

36. Jacobson NS, Truax P. Clinical Significance: A Statistical Approach to Defining Meaningful Change in Psychotherapy Research. J Consult Clin Psychol. 1991;59(1):12–9.

37. Beshai S, Dobson KS, Bockting CLH, Quigley L. Relapse and recurrence prevention in depression: Current research and future prospects. Clin Psychol Rev. 2011;31(8):1349–60.

38. Fusar-Poli P, Hijazi Z, Stahl D, Steyerberg EW. The Science of Prognosis in Psychiatry: A Review. JAMA Psychiatry. 2018;75(12):1280–8.

39. Buckman JEJ, Underwood A, Clarke K, Saunders R, Hollon SD, Fearon P, et al. Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and meta-synthesis. Clin Psychol Rev. 2018;64:13–38.

40. Wojnarowski C, Firth N, Finegan M, Delgadillo J. Predictors of depression relapse and recurrence after cognitive behavioural therapy: a systematic review and meta-analysis. Behav Cogn Psychother. 2019;47(5):514–29.

41. Kessler RC. The potential of predictive analytics to provide clinical decision support in depression treatment planning. Curr Opin Psychiatry. 2018;31(1):32–9.

42. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch Intern Med. 2006;166(10):1092–7.

43. Groenwold RHH, Moons KGM, Pajouheshnia R, Altman DG, Collins GS, Debray TPA, et al. Explicit inclusion of treatment in prognostic modeling was recommended in observational and randomized settings. J Clin Epidemiol. 2016;78:90–100.

44. Pajouheshnia R, Peelen LM, Moons KGM, Reitsma JB, Groenwold RHH. Accounting for treatment use when validating a prognostic model: A simulation study. BMC Med Res Methodol. 2017;17(1):1–12.

45. Van Smeden M, De Groot JAH, Moons KGM, Collins GS, Altman DG, Eijkemans MJC, et al. No rationale for 1 variable per 10 events criterion for binary logistic regression analysis. BMC Med Res Methodol. 2016;16(1):1–12.

46. Riley RD, Ensor J, Snell KIE, Harrell FE, Martin GP, Reitsma JB, et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020 Mar 18;m441.

47. Riley RD, Snell KIE, Ensor J, Burke DL, Harrell FE, Moons KGM, et al. Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med. 2018;1–21.

48. Hughes RA, Heron J, Sterne JAC, Tilling K. Accounting for missing data in statistical analyses: multiple imputation is not always the answer. Int J Epidemiol. 2019 Mar 16;

49. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377–99.

50. Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: A tool to assess risk of bias and applicability of prediction model studies: Explanation and elaboration. Ann Intern Med. 2019;170(1):W1–33.

51. Harrell Jr FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. eBook. Vol. 13, Statistical Methods in Medical Research. Springer International Publishing Switzerland; 2015.

52. Binder H, Sauerbrei W, Royston P. Comparison between splines and fractional polynomials for multivariable model building with continuous covariates: A simulation study with continuous response. Stat Med. 2013;32(13):2262–77.

53. Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. BMJ. 2016;352:3–7.

54. Royston P, Parmar MKB, Sylvester R. Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. Stat Med. 2004;23(6):907–26.

55. Steyerberg EW, Harrell FE. Prediction models need appropriate internal, internal-external, and external validation. Vol. 69, Journal of Clinical Epidemiology. Elsevier USA; 2016. p. 245–7.

56. Hingorani AD, Van Der Windt DA, Riley RD, Abrams K, Moons KGM, Steyerberg EW, et al. Prognosis research strategy (PROGRESS) 4: Stratified medicine research. BMJ. 2013;346:1–9.

57. Cuijpers P, Cuijpers P. Expert Review of Neurotherapeutics Measuring success in the treatment of depression : what is most important to patients ? Measuring success in the treatment of depression : what is most important to. Expert Rev Neurother. 2020;00(00):1–3.

58. Moriarty AS, Gilbody S, McMillan D, Manea L. Screening and case finding for major depressive disorder using the Patient Health Questionnaire (PHQ-9): A meta-analysis. Gen Hosp Psychiatry. 2015;37(6):567–76.

59. Berlanga C, Heinze G, Torres M, Apiquián R, Caballero A. Personality and clinical predictors of recurrence of depression. Psychiatr Serv. 1999;50(3):376–80.